Compare Adaptive Biotechnologies Corp (ADPT) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Kimberly Clark Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Kimberly Clark Corp trades at $111.45 (market cap $38.09B). The key difference: Kimberly Clark Corp is far larger — about 11.4× Adaptive Biotechnologies Corp's market cap, and Kimberly Clark Corp pays a 4.46% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KMB | |
|---|---|---|
Market Cap | $3.33B | $38.09B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $136.77 |
52-Week Low | $10.24 | $93.05 |
Enterprise Value | $3.19B | $44.63B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Kimberly-Clark (KMB) trades at $114.74, up 0.02% on the day, showing stable performance near its consensus price target. The stock maintains a bullish technical signal with strong moving average support, though oscillators indicate potential overbought conditions. Fundamentally, the company demonstrates consistent earnings beats with Q1 2026 EPS of $1.97 exceeding expectations, supported by a healthy 12.8% net income margin and robust ROE of 146.29%. Recent corporate actions include a $1.28 dividend payment scheduled for July 2026.
KMB presents a mixed outlook with strong profitability metrics offset by revenue declines from $20.4B in 2023 to $16.45B in 2025. Investment appeal includes a 5%+ dividend yield and analyst consensus leaning toward Hold (58.06%) with a $109.20 price target. Key risks include margin pressure from input costs and competitive threats from new market entrants like Arbex. Institutional sentiment remains cautious despite technical strength, requiring monitoring of Q2 2026 earnings due August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
